Over-ground walking or robot-assisted gait training in people with .multiple sclerosis: does the effect depend on baseline walking speed and disease related disabilities? A systematic review and meta-regression.

Meta-regression, systematic review Multiple sclerosis Over-ground walking Robot-assisted gait training

Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
08 May 2019
Historique:
received: 19 07 2017
accepted: 29 04 2019
entrez: 10 5 2019
pubmed: 10 5 2019
medline: 14 6 2019
Statut: epublish

Résumé

It was suggested that robot-assisted gait training (RAGT) should not be routinely provided to disabled patients in place of conventional over-ground walking training (CGT). There exist several randomised controlled trials reporting on RAGT for people with multiple sclerosis. However, the effectiveness of RAGT varies between studies with the effectiveness pointing in different directions. It might be possible that the effectiveness of RAGT and CGT depends on the disease related disabilities of the people included in the clinical studies. We aimed to systematically search RCTs and to perform a meta-regression to compare the effects of robot-assisted gait training in people with less and higher disease related disabilities. The Expanded Disability Status Scale (EDSS) scores were used to classify level of disability. A systematic search was developed to search four electronic databases (MEDLINE, CENTRAL, EMBASE and CINAHL) for eligible articles. A random effects model was applied to meta-analyse the effects of the interventions. Meta-regression was performed with an uni-variable random effects model using baseline walking speed and EDSS to predict the between group effect. The search on databases resulted in 596 records and finally nine studies were included into the review. The pooled estimates of the effects for performance over short and long distance tests were small and non-significant: -0.08 SMD (95% CI: -0.51 to 0.35) and - 0.24 SMD (95% CI: -0.67 to 0.19). Neither baseline walking speed or disease related disability were related to the mean effect size. Future studies are needed to help clinicians to decide, which intervention should be allocated to the individual patient.

Sections du résumé

BACKGROUND BACKGROUND
It was suggested that robot-assisted gait training (RAGT) should not be routinely provided to disabled patients in place of conventional over-ground walking training (CGT). There exist several randomised controlled trials reporting on RAGT for people with multiple sclerosis. However, the effectiveness of RAGT varies between studies with the effectiveness pointing in different directions. It might be possible that the effectiveness of RAGT and CGT depends on the disease related disabilities of the people included in the clinical studies. We aimed to systematically search RCTs and to perform a meta-regression to compare the effects of robot-assisted gait training in people with less and higher disease related disabilities. The Expanded Disability Status Scale (EDSS) scores were used to classify level of disability.
METHODS METHODS
A systematic search was developed to search four electronic databases (MEDLINE, CENTRAL, EMBASE and CINAHL) for eligible articles. A random effects model was applied to meta-analyse the effects of the interventions. Meta-regression was performed with an uni-variable random effects model using baseline walking speed and EDSS to predict the between group effect.
RESULTS RESULTS
The search on databases resulted in 596 records and finally nine studies were included into the review. The pooled estimates of the effects for performance over short and long distance tests were small and non-significant: -0.08 SMD (95% CI: -0.51 to 0.35) and - 0.24 SMD (95% CI: -0.67 to 0.19). Neither baseline walking speed or disease related disability were related to the mean effect size.
DISCUSSION CONCLUSIONS
Future studies are needed to help clinicians to decide, which intervention should be allocated to the individual patient.

Identifiants

pubmed: 31068151
doi: 10.1186/s12883-019-1321-7
pii: 10.1186/s12883-019-1321-7
pmc: PMC6506946
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

93

Références

J Clin Epidemiol. 2000 Nov;53(11):1119-29
pubmed: 11106885
J Clin Epidemiol. 2002 Jan;55(1):86-94
pubmed: 11781126
Neurology. 2003 Jan 14;60(1):31-6
pubmed: 12525714
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Mult Scler. 2005 Aug;11(4):485-91
pubmed: 16042234
Disabil Rehabil. 2005 Nov 30;27(22):1365-71
pubmed: 16372431
Mult Scler. 2006 Oct;12(5):620-8
pubmed: 17086909
Mult Scler. 2008 Apr;14(3):383-90
pubmed: 17942508
Mult Scler. 2008 Mar;14(2):231-6
pubmed: 17942510
Neurorehabil Neural Repair. 2008 Nov-Dec;22(6):661-71
pubmed: 18971381
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
J Rehabil Res Dev. 2011;48(4):483-92
pubmed: 21674396
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Neurorehabil Neural Repair. 2012 Mar-Apr;26(3):212-21
pubmed: 22140197
Mult Scler. 2012 Jun;18(6):881-90
pubmed: 22146609
Neurorehabil Neural Repair. 2012 May;26(4):308-17
pubmed: 22412172
Mult Scler Int. 2012;2012:240274
pubmed: 22701177
Mult Scler. 2012 Jul;18(7):914-24
pubmed: 22740603
Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):1007-22
pubmed: 23917098
NeuroRehabilitation. 2013;33(4):555-63
pubmed: 24018369
J Neurol Phys Ther. 2013 Dec;37(4):187-93
pubmed: 24189336
Phys Med Rehabil Clin N Am. 2013 Nov;24(4):573-92
pubmed: 24314677
Front Hum Neurosci. 2014 May 22;8:318
pubmed: 24904361
Mult Scler. 2016 Mar;22(3):373-84
pubmed: 26658817
Mult Scler. 2017 Apr;23(5):696-703
pubmed: 27486219
Neuropsychiatr Dis Treat. 2017 May 15;13:1303-1311
pubmed: 28553117
Gait Posture. 2018 Mar;61:445-452
pubmed: 29486362
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237

Auteurs

Martin Sattelmayer (M)

University of Applied Sciences and Arts Western Switzerland Valais (HES-SO Valais-Wallis), School of Health Sciences, Leukerbad, Switzerland. martin.sattelmayer@hevs.ch.

Odile Chevalley (O)

University of Applied Sciences and Arts Western Switzerland Valais (HES-SO Valais-Wallis), School of Health Sciences, Leukerbad, Switzerland.

Ruedi Steuri (R)

University of Applied Sciences and Arts Western Switzerland Valais (HES-SO Valais-Wallis), School of Health Sciences, Leukerbad, Switzerland.

Roger Hilfiker (R)

University of Applied Sciences and Arts Western Switzerland Valais (HES-SO Valais-Wallis), School of Health Sciences, Leukerbad, Switzerland. roger.hilfiker@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH